Oramed Pharmaceuticals Inc (ORMP) FinancialsORMPFinancialOramed Pharmaceuticals Inc

Evaluating the bottom line, Oramed Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 58.04%, provide a clear picture of how effectively ORMP converts its operational activities into shareholder value.

In the context of the broader market, ORMP competes directly with industry leaders such as IPHA and IMUX. With a market capitalization of $209.23M, it holds a significant position in the sector. When comparing efficiency, ORMP's gross margin of N/A stands against IPHA's 3.59% and IMUX's N/A. Such benchmarking helps identify whether Oramed Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Oramed Pharmaceuticals reported a profit of $10 million in Q4 2026, with a net income of $0.24 per share. The company achieved a profit of $64.1 million for the year, reflecting strong growth despite only $2 million in revenue, highlighting operational efficiency.